Literature DB >> 32522441

The miR-218/GAB2 axis regulates proliferation, invasion and EMT via the PI3K/AKT/GSK-3β pathway in prostate cancer.

Juanhua Tian1, Haibao Zhang2, Lijun Mu2, Meiyu Wang3, Xudong Li4, Xinwei Zhang2, Enxu Xie2, Minghai Ma2, Dapeng Wu5, Yuefeng Du6.   

Abstract

Altered expression of microRNA (miRNA) is associated with the occurrence and metastasis of various tumors. We previously found that miR-218 inhibits tumor angiogenesis through the RICTOR/VEGFA axis in prostate cancer (PCa). In this study, we determined that miR-218 also had a negative effect on cell growth, migration, and invasion ability in PCa. Our data showed that miR-218 bound to the Grb2-associated binding protein 2 (GAB2) 3'-UTR region and inhibited GAB2 expression. As a novel downstream target of miR-218, GAB2 has been reported to be involved in the occurrence and development of various human tumors, but its role in the progression and metastasis of PCa has not been addressed. We demonstrated for the first time that the expression of GAB2 in the PCa cell lines was increased, while knocking down GAB2 significantly inhibited cell growth, metastatic ability and EMT process in PCa. In addition, the recovery of GAB2 could reverse the changes in the biological function of PCa cells caused by the ectopic expression of miR-218. Mechanistically, miR-218-mediated GAB2 transcriptional suppression significantly inhibited the activity of the PI3K/AKT/GSK-3β pathway, whose abnormal activation was found to be related to the malignant progression of PCa. Taken together, our findings suggest that the miR-218/GAB2 axis may become a novel prognostic indicator and potential therapeutic target in PCa.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial-mesenchymal transition; GAB2; Metastasis; Proliferation; Prostate cancer; miR-218

Year:  2020        PMID: 32522441     DOI: 10.1016/j.yexcr.2020.112128

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  ECRG4 acts as a tumor suppressor in nasopharyngeal carcinoma by suppressing the AKT/GSK3β/β-catenin signaling pathway.

Authors:  Zhengyuan Yang; Xiajun Ye; Yujie Zhang; Yiteng Huang; Jian Chen; Yunzhu Zeng; Jiongyu Chen
Journal:  Cytotechnology       Date:  2022-01-27       Impact factor: 2.058

2.  Neuroprotective Effects of ZiBuPiYin Recipe on db/db Mice via PI3K-Akt Signaling Pathway by Activating Grb2.

Authors:  Wei-Ming Ren; Ze-Bin Weng; Xin Li; Li-Bin Zhan
Journal:  Neural Plast       Date:  2021-01-30       Impact factor: 3.599

Review 3.  Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors.

Authors:  Kaibo Guo; Yuqian Feng; Xueer Zheng; Leitao Sun; Harpreet S Wasan; Shanming Ruan; Minhe Shen
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

4.  Effects of miR-103a-3p Targeted Regulation of TRIM66 Axis on Docetaxel Resistance and Glycolysis in Prostate Cancer Cells.

Authors:  Qiang Yi; Junfeng Wei; Yangzhou Li
Journal:  Front Genet       Date:  2022-02-08       Impact factor: 4.599

Review 5.  Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?

Authors:  Folake Orafidiya; Lin Deng; Charlotte Lynne Bevan; Claire Emily Fletcher
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

6.  Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells.

Authors:  Juan Li; Nan Yang; Xiaolei Tian; Linglong Ouyang; Man Jiang; Shufang Zhang
Journal:  Mol Med Rep       Date:  2022-07-27       Impact factor: 3.423

Review 7.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26

8.  Role of microRNA‑218‑5p in sevoflurane‑induced protective effects in hepatic ischemia/reperfusion injury mice by regulating GAB2/PI3K/AKT pathway.

Authors:  Hui Ji; Hui Li; Haixia Zhang; Zhijun Cheng
Journal:  Mol Med Rep       Date:  2021-11-02       Impact factor: 2.952

9.  Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.

Authors:  Xiang Ding; Xu Xu; Xue-Feng He; Ye Yuan; Chuang Chen; Xin-Yu Shen; Sai Su; Zhang Chen; Song-Tao Xu; Yu-Hua Huang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.